tiprankstipranks
Advertisement
Advertisement
NewAmsterdam Pharma reports Q1 revenue $3.04M, consensus $925,520
PremiumThe FlyNewAmsterdam Pharma reports Q1 revenue $3.04M, consensus $925,520
4M ago
NewAmsterdam Pharma management to meet with Piper Sandler
Premium
The Fly
NewAmsterdam Pharma management to meet with Piper Sandler
4M ago
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
Premium
Company Announcements
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
5M ago
NewAmsterdam Pharma management to meet virtually with Piper Sandler
PremiumThe FlyNewAmsterdam Pharma management to meet virtually with Piper Sandler
7M ago
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
Premium
The Fly
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
7M ago
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
Premium
Ratings
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100